New drug trial targets aggressive lung cancer after standard treatments fail
NCT ID NCT06758700
Summary
This study is testing whether the drug teniposide can help control advanced small cell lung cancer that has worsened despite standard chemotherapy. It is for patients whose cancer has a specific genetic feature called 'c-Myc-driven.' The main goal is to see if the drug shrinks tumors and is safe for these patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital, Shanghai, China
RECRUITINGShanghai, Shanghai Municipality, 200331, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.